Mechanisms underlying altered extracellular nucleotide-induced contractions in mesenteric arteries from rats in later-stage type 2 diabetes: Effect of ANG II type 1 receptor antagonism

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 5, 2011, Pages

  Ishida, Keiko ^a   Matsumoto, Takayuki ^a   Taguchi, Kumiko ^a   Kamata, Katsuo ^a   Kobayashi, Tsuneo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Endothelium derived contracting factor; Goto kakizaki rat; Purinoceptor

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLUCOSE; INSULIN; LOSARTAN; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; SURAMIN;

ANIMAL EXPERIMENT; ARTERY CONSTRICTION; ARTICLE; BLOOD; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; MESENTERIC ARTERY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; RAT;

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DINOPROST; DINOPROSTONE; DISEASE MODELS, ANIMAL; GROUP IV PHOSPHOLIPASES A2; LOSARTAN; MALE; MEMBRANE PROTEINS; MESENTERIC ARTERY, SUPERIOR; PHOSPHORYLATION; PURINERGIC P2 RECEPTOR ANTAGONISTS; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P2; RECEPTORS, PURINERGIC P2Y2; SIGNAL TRANSDUCTION; SUPEROXIDES; URIDINE TRIPHOSPHATE; VASOCONSTRICTION;

EID: 80355127955     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00502.2011     Document Type: Article

References (65)

1. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58: 281-341, 2006.
2. Alvarez Y, Perez-Giron JV, Hermanz R, Briones AM, Garcia-Redondo A, Beltran A, Alonso MJ, Salaices M. Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats. J Pharmacol Exp Ther 32: 381-388, 2007.
3. Baek EB, Yoo HY, Park SJ, Kim HS, Kim SD, Earm YE, Kim SJ. Luminal ATP-induced contraction of rabbit pulmonary arteries and role of purinoceptors in the regulation of pulmonary arterial pressure. Pflügers Arch 457: 281-291, 2008.
4. Banes-Berceli AK, Ketsawatsomkron P, Ogbi S, Patel B, Pollock DM, Marrero MB. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol 293: H1291-H1299, 2007.
5. Bartoo AC, Nelson MT, Mawe GM. ATP induces guinea pig gallbladder smooth muscle excitability via the P2Y4 receptor and COX-1 activity. Am J Physiol Gastrointest Liver Physiol 294: G1362-G1368, 2008.
6. Beltran AE, Briones AM, Garcia-Redondo AB, Rodriguez C, Miguel M, Alvarez Y, Alonso MJ, Martinez-Gonzalez J, Salaices M. p38 MAPK contributes to angiotensin II-induced COX-2 expression in aortic fibroblasts from normotensive and hypertensive rats. J Hypertens 27: 142-154, 2009.
7. Berenbaum F, Humbert L, Bereziat G, Thirion S. Concomitant recruitment of ERK1/2 and p38 MAPK signaling pathway is required for activation of cytoplasmic phospholipase A2 via ATP in articular chondro-cytes. J Biol Chem 278: 13680-13687, 2003.
8. Bhattacharyya DK, Lecomte M, Dunn J, Morgans DJ, Smith WL. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxy-genase-1) by valerylsalicylic acid. Arch Biochem Biophys 317: 19-24, 1995.
9. Brabury DA, Newton R, Zhu YM, El-Haroun H, Corbett L, Knox AJ. Cyclooxygenase-2 induction by bradykinin in human pulmonary artery smooth muscle cells is mediated by the cyclic AMP response element through a novel autocrine loop involving endogenous prostaglandin E2 E-prostanoid 2 (EP2), and EP4 receptors. J Biol Chem 278: 49954-49964, 2003.
10. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 58: 58-86, 2006.
11. Burnstock G. Purine and pyrimidine receptors. Cell Mol Life Sci 64: 1471-1483, 2007.
12. Cavaliere F, Sancesario G, Bernardi G, Volonte C. Extracellular ATP and nerve growth factor intensify hypoglycemia-induced cell death in primary neurons: role of P2 and NGFRp75 receptors. J Neurochem 83: 1129-1138, 2002.
13. Chrysant SG, Chrysant GS. The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens 8: 261-268, 2006.
14. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal 4: 1-20, 2008.
15. Feletou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol doi:10.1111/ j.1476-5381.2011.01276.x.
16. Freeman EJ, Ruehr ML, Dorman RV. ANG II-induced translocation of cytosolic PLA2 to the nucleus in vascular smooth muscle cells. Am J Physiol Cell Physiol 274: C282-C288, 1998.
17. Freeman EJ, Sheakley ML, Clements RJ. Angiotensin II-dependent growth of vascular smooth muscle cells requires transactivation of the epidermal growth factor receptor via a cytosolic phospholipase A2-medi-ated release of arachidonic acid. Arch Biochem Biophys 498: 50-56, 2010.
18. Gluais P, Vanhoutte PM, Feletou M. Mechanisms underlying ATP-induced endothelium-dependent contractions in the SHR aorta. Eur J Pharmacol 556: 107-114, 2007.
19. Goto Y, Kakizaki M, Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med 119: 85-90, 1976.
20. Gronros J, Jung C, Lundberg JO, Cerrato R, Ostenson CG, Pernow J. Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol Heart Circ Physiol 300: H1174-H1181, 2011.
21. Gui Y, Walsh MP, Jankowski V, Jankowski J, Zheng XL. Up4A stimulates endothelium-independent contraction of isolated rat pulmonary artery. Am J Physiol Lung Cell Mol Physiol 294: L733-L738, 2008.
22. Gupte S, Labinskyy N, Gupte R, Csiszar A, Ungvari Z, Edwards JG. Role of NAD(P)H oxidase in superoxide generation and endothelial dysfunction in Goto-Kakizaki (GK) rats as a model of nonobese NIDDM. PLos One 5: e11800, 2010.
23. Harhun MI, Povstyan OV, Gordienko DV. Purinoceptor-mediated current in myocytes from renal resistance arteries. Br J Pharmacol 160: 987-997, 2010.
24. Huang A, Yan C, Suematsu N, Cuevas A, Yang YM, Kertowidjojo E, Hintze TH, Kaley G, Sun D. Impaired flow-induced dilation of coronary arterioles of dogs fed a low-salt diet: roles of ANG II, PKC, and NAD(P)H oxidase. Am J Physiol Heart Circ Physiol 299: H1476-H1483, 2010.
25. Inscho EW, LeBlanc EA, Pham BT, White SM, Imig JD. Purinoceptor-mediated calcium signaling in preglomerular smooth muscle cells. Hypertension 33: 195-200, 1999.
26. Isenovic ER, Fretaud M, Dobutovic B, Sudar E, Smiljanic K, Zaric B, Trpkovic A, Marche P. A novel hypothesis regarding the possible involvement of cytosolic phospholipase 2 in insulin-stimulated proliferation of vascular smooth muscle cells. Cell Biol Int 33: 386-392, 2009.
27. Judkins CP, Sobey CG, Dang TT, Miller AA, Dusting GJ, Drummond GR. NADPH-induced contractions of mouse aorta do not involve NADPH oxidase: a role for P2X receptors. J Pharmacol Exp Ther 317: 644-650, 2006.
28. Kazuyama E, Saito M, Kinoshita Y, Satoh I, Dimitriadis F, Satoh K. Endothelial dysfunction in the early- and late-stage type 2 diabetic Goto-Kakizaki rat aorta. Mol Cell Biochem 332: 95-102, 2009.
29. Kobayashi T, Matsumoto T, Ooishi K, Kamata K. Differential expression of a2D-adrenoceptor and eNOS in aortas from early and later stages of diabetes in Goto-Kakizaki rats. Am J Physiol Heart Circ Physiol 287: H135-H143, 2004.
30. 2+ transient in mesenteric small arteries. Am J Physiol Heart Circ Physiol 291: H3106-H3113, 2006.
31. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell 72: 269-278, 1993.
32. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; Study Group LIFE. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomized trial against atenolol. Lancet 359: 1004-1010, 2002.
33. Mamedova LK, Wang R, Besada P, Liang BT, Jacobson KA. Attenuation of apoptosis in vitro and ischemia/reperfusion injury in vivo in mouse skeletal muscle by P2Y6 receptor activation. Pharmacol Res 58: 232-239, 2008.
34. Matsumoto T, Ishida K, Nakayama N, Kobayashi T, Kamata K. Involvement of NO and MEK/ERK pathway in enhancement of endothe-lin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol 296: H1388-H1397, 2009.
35. Matsumoto T, Ishida K, Nakayama N, Taguchi K, Kobayashi T, Kamata K. Mechanisms underlying the losartan treatment-induced improvement in the endothelial dysfunction seen in mesenteric arteries from type 2 diabetic rats. Pharmacol Res 62: 271-281, 2010.
36. + channels in mesenteric artery from type 2 diabetic GK rat. J Pharmacol Sci 112: 299-309, 2010.
37. Matsumoto T, Ishida K, Taguchi K, Kobayashi T, Kamata K. Short-term angiotensin-1 receptor antagonism in type 2 diabetic Goto-Kakizaki rats normalizes endothelin-1-induced mesenteric artery contraction. Peptides 31: 609-617, 2010.
38. Matsumoto T, Kakami M, Noguchi E, Kobayashi T, Kamata K. Imbalance between endothelium-derived relaxing and contracting factors in mesenteric arteries from aged OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 293: H1480-H1490, 2007.
39. Matsumoto T, Nakayama N, Ishida K, Kobayashi T, Kamata K. Eicosapentaenoic acid improves imbalance between vasodilator and vasoconstrictor actions of endothelium-derived factors in mesenteric arteries from rats at chronic stage of type 2 diabetes. J Pharmacol Exp Ther 329: 324-334, 2009b.
40. Matsumoto T, Noguchi E, Ishida K, Kobayashi T, Yamada N, Kamata K. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 295: H1165-H1176, 2008.
41. Nori S, Fumagalli L, Bo X, Bogdanov Y, Burnstock G. Coexpression of mRNAs for P2X1, P2X2 and P2X4 receptors in rat vascular smooth muscle: an in situ hybridization and RT-PCR study. J Vasc Res 35: 179-185, 1998.
42. North RA. Molecular physiology of P2X receptors. Physiol Rev 82: 1013-1067, 2002.
43. 2+ mobilization, membrane hyperpolarization and nitric oxide production in human vascular endothelial cells. Cell Calcium 49: 240-248, 2011.
44. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 50: 413-492, 1998.
45. Ralevic V, Burnstock G. Relative contribution of P2U- and P2Y-puri-noceptors to endothelium-dependent vasodilatation in the golden hamster isolated mesenteric arterial bed. Br J Pharmacol 117: 1797-1802, 1996.
46. Ruan YC, Wang Z, Du JY, Zuo WL, Guo JH, Zhang J, Wu ZL, Wong HY, Chung YW, Chan HC, Zhou WL. Regulation of smooth muscle contractility by the epithelium in rat vas deferens: role of ATP-induced release of PGE2. J Physiol 586: 4843-4857, 2008.
47. Sachidanandam K, Elgebaly MM, Harris AK, Hutchinson JR, Mez-zetti EM, Portik-Dobos V, Ergul A. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes. Am J Physiol Heart Circ Physiol 294: H2743-H2749, 2008.
48. Soto F, Lambrecht G, Nickel P, Stuhmer W, Busch AE. Antagonistic properties of the suramin analogue NF023 at heterogously expressed P2Y receptors. Neuropharmacology 38: 141-149, 1999.
49. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286: H1597-H1602, 2004.
50. Serpillon S, Floyd BC, Gupte RS, George S, Kozicky M, Neito V, Recchia F, Stanley W, Wolin MS, Gupte SA. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol 297: H153-H162, 2009.
51. Stanke-Labesque F, Mallaret M, Lefebvre B, Hardy G, Caron F, Bessard G. 2-Arachidonoyl glycerol induces contraction of isolated rat aorta: role of cyclooxygenase-derived products. Cardiovasc Res 63: 155-160, 2004.
52. _/_ knockout mice. J Cardiovasc Pharmacol 46: 761-765, 2005.
53. Tang EH, Leung FP, Huang Y, Feletou M, So KF, Man RY, Vanhoutte PM. Calcium and reactive oxygen species increase in endothelial cells in response to releasers of endothelium-derived contracting factor. Br J Pharmacol 151: 15-23, 2007.
54. Tang EH, Vanhoutte PM. Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. Pharmacol Ther 112: 140-149, 2009.
55. Thaning P, Bune LT, Hellsten Y, Pilegaard H, Saltin B, Rosenmeier JB. Attenuated purinergic receptor function in patients with type 2 diabetes. Diabetes 59: 182-189, 2010.
56. Turner CM, Vonend O, Chan C, Burnstock G, Unwin RJ. The pattern of distribution of selected ATP-sensitive P2 receptor subtypes in normal rat kidney: an immunohistological study. Cell Tissues Organs 175: 105-117, 2003.
57. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol 196: 193-222, 2009.
58. Vanhoutte PM, Tang EH. Endothelium-dependent contractions: when a good guy turns bad! J Physiol 586: 5295-5304, 2008.
59. Wang D, Chabrashvilli T, Wilcox CS. Enhanced contractility of renal afferent arterioles from angiotensin-infused rabbit: roles of oxidative stress, thromboxane prostanoid receptors, and endothelium. Circ Res 94: 1436-1442, 2004.
60. Wang HD, Pagano PJ, Du Y, Cayatte AJ, Quinn MT, Brecher P, Cohen RA. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 82: 810-818, 1998.
61. Wang L, Karisson L, Moses S, Hultgardh-Nilsson A, Andersson M, Borna C, Gudbjartsson T, Jem S, Erlinge D. P2 receptor expression profiles in human vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 40: 841-853, 2002.
62. Wong SL, Leung FP, Lau CW, Au CL, Yung LM, Yao X, Chen ZY, Vanhoutte PM, Gollasch M, Huang Y. Cyclooxygenase-2-derived prostaglandin F2a mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res 104: 228-235, 2009.
63. +-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest 96: 733-740, 1995.
64. Yang D, Feletou M, Levens N, Zhang JN, Vanhoutte PM. A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. Hypertension 41: 143-148, 2003.
65. Zhou MS, Schulman IH. Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial. Vasc Health Risk Manag 5: 361-368, 2009.